Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 26, 2022
Emerging Company Profile
Kinaset: targeting JAK to treat both asthma phenotypes
With a $40M series A and former head of Pulmatrix Robert Clarke as CEO, Kinaset is going upstream in the inflammatory pathway to treat both major types of asthma
BioCentury | Nov 30, 2020
Finance
Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor
Kinaset is launching with a $40 million series A led by 5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in
BioCentury | Apr 8, 2013
Strategy
AstraZeneca's reset
Five areas where AstraZeneca will invest to revive long-term growth
Items per page:
1 - 10 of 11